Correction: Holist Integ Oncol 3, 15 (2024)

https://doi.org/10.1007/s44178-024-00079-8


Following publication of the original article [1], the authors reported errors in Table 2, which have been corrected from:

Table 2 Characteristics of AML patients and controls

To:

Table 2 Characteristics of AML patients and controls

In Table 2, for the HGB, “ > 60 g/L” has been replaced by “ ≥ 60 g/L”, and “ ≤ 60 g/L” replaced by “ < 60 g/L”. For the Risk stratification, the patients in adverse group should have been “68” instead of “67”, and the description in Result 3.1 (Page 4) has been corrected accordingly. For the Bone marrow blast, the patients in ≥ 42% group should have been “231” instead of “131”. The other elements of the table and the interpretation of the results remain unchanged.

In addition, the author found an error in Fig. 1 legend, which has been corrected from: The overall survival of AML patients with TT, AA, and TA genotypes in IKKB rs3747811 under different models. a codominant model, (b) dominant model, to: The overall survival of AML patients with TT, AA, and TA genotypes in IKKB rs3747811 under different models. (a) dominant model, (b) codominant model.

The original article [1] has been corrected.